FDA Allows Use of Kalydeco in Children Under Two Years Old

The U.S. Food and Drug Administration (FDA) has approved ivacaftor (KALYDECO) to be used in children with cystic fibrosis ages under the age of 2 years old who have at least 1 mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is...

Innovation in Newborn Screening

  Richard West, Founder and CEO of Baebies, discusses the public health program of newborn screening. Screening programs are often run by state or national governing bodies with the goal of screening all infants born in the jurisdiction. The number of diseases...

FDA Approves First Treatment for Rare Adrenal Tumors

The Food and Drug Administration (FDA) approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) that cannot be surgically...
  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.